Marco Cippitelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in multiple myeloma. modulation by bromodomain and Extra-Terminal (BET) protein inhibitors	CELL DEATH & DISEASE	2019
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms	THE FASEB JOURNAL	2019
The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress	CANCERS	2019
Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene	FRONTIERS IN IMMUNOLOGY	2019
NKG2D and its ligands: one for all, all for one	FRONTIERS IN IMMUNOLOGY	2018
Drug-induced senescent Multiple Myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL-15 trans-presentation	CANCER IMMUNOLOGY RESEARCH	2018
MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma	FRONTIERS IN IMMUNOLOGY	2018
Translating the anti-myeloma activity of Natural Killer cells into clinical application	CANCER TREATMENT REVIEWS	2018
Key role of the CD56lowCD16low Natural Killer cell subset in the recognition and killing of Multiple Myeloma cells	CANCERS	2018
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells	ONCOIMMUNOLOGY	2017
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: role of HSP70/TLR2/NF-kB axis	ONCOIMMUNOLOGY	2017
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells	SCIENTIFIC REPORTS	2017
Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance.	FRONTIERS IN IMMUNOLOGY	2017
Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer	CURRENT MEDICINAL CHEMISTRY	2016
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells. role of cMYC-IRF4-miR-125b interplay	JOURNAL OF HEMATOLOGY & ONCOLOGY	2016
Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression	JOURNAL OF IMMUNOLOGY	2016
Targeting NKG2D and NKp30 ligands shedding to improve NK cell–based immunotherapy	CRITICAL REVIEWS IN IMMUNOLOGY	2016
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma	BIOMED RESEARCH INTERNATIONAL	2015
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma	ONCOTARGET	2015
Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells	SCIENCE SIGNALING	2015

ERC

LS6_1
LS6_3

KET

Life-science technologies & biotechnologies

Keywords

cancer immunotherapy

multiple myeloma

natural killer

Progetti di Ricerca

Harnessing NK cells by genetic and epigenetic rerouting to overcome Multiple Myeloma immune evasion.